This may sound familiar if you’re subscribed to my AI Prognosis newsletter, but it’s worth repeating: I finally found time to ...

Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in ...

Eli Lilly said this morning that its experimental obesity pill orforglipron fell short of expectations in a late-stage trial, delivering 11.2% weight loss over 72 weeks — less than the 15% to 21% ...

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic ...

One of the most notable accomplishments of the first Trump Administration was its willingness to take on the status quo of ...

Propel Health Communications, a 2025 MM+M Agency 100 honoree, hired Christopher Thorn as SVP, creative director and Lauren ...

The amount of frozen funds could be as high as $200 million, or potentially more than $300 million, according to two ...

Overall, the initial steps of the wind-down will result the in the cancellation of nearly $500 million. Not all mRNA related ...